This article is part of the supplement: AIDS Vaccine 2009
Poster presentation
P04-03. Cross-clade neutralization analysis of plasmas from clade B, C and CRF01_AE HIV-infected donors
1 AIDS/Viral Immunology, Torrey Pines Institute, San Diego, CA, USA
2 MonoGramBio, San Francisco, CA, USA
3 Simon Fraser University, Vancouver, Canada
4 Los Alamos National Laboratory, Los Alamos, NM, USA
5 National Institute for Communicable Diseases, Johannesburg, South Africa
6 Beth Israel Medical Center, Boston, MA, USA
7 University of Agricultural Sciences, Vienna, Austria
8 University of California, San Diego, La Jolla, CA, USA
9 HIV Bioinformatic Center, Bangkok, Thailand
10 The Scripps Research Institute, La Jolla, CA, USA
Retrovirology 2009, 6(Suppl 3):P31 doi:10.1186/1742-4690-6-S3-P31
Published: 22 October 2009First paragraph (this article has no abstract)
The genetic diversity of HIV-1, particularly in Env, is considered a major challenge for vaccine researchers, especially those attempting to elicit broadly neutralizing antibodies. Categorizing HIV strains into neutralization serotypes may help determine the requirements for maximal vaccine immune coverage. HIV is divided into clades, based on genetic relatedness, principally in Env. Investigations as to whether these clades might help to define neutralizing serotypes have so far mostly been confined to small studies, and have been hampered by the challenges of traditional PBMC-blast neutralization assays. The observation that some HIV+ plasmas neutralize viruses from several major clades hints of an undercurrent of conserved neutralization, but its potency relative to any clade-restricted activity is unknown. High throughput pseudovirus neutralization assays provide a way to investigate.